Linked Life Data

20720210

Source:http://linkedlifedata.com/resource/pubmed/id/20720210

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2010-9-3
pubmed:abstractText
Mucosal (nasal or oral) administration of anti-CD3 mAb is effective in ameliorating animal models of autoimmunity (experimental autoimmune encephalomyelitis, diabetes, and lupus) by inducing LAP(+) regulatory T cells. We tested this approach in an arthritis model using type II collagen. We found that nasal anti-CD3 was more effective than oral anti-CD3 in attenuating the development of arthritis. Nasal anti-CD3 induced a LAP(+) regulatory T cell that secreted high levels of IL-10 and suppressed collagen-specific T cell proliferation and anti-collagen Ab production. However, neither nasal nor oral anti-CD3 attenuated disease when given to animals with ongoing arthritis, and this was associated with a lack of induction of LAP(+) regulatory T cells. We found, however, that coadministration of a novel emulsome adjuvant, which enhances Th2 responses, resulted in the induction of LAP(+) regulatory T cells and suppression of ongoing arthritis by both nasal and oral anti-CD3. Suppression of arthritis by mucosal anti-CD3 was associated with less joint damage, a decrease of TNF-alpha and IFN-gamma mRNA expression in joints, and a reduction in anti-collagen Abs. These results demonstrate that mucosal anti-CD3 therapy may serve as a therapeutic approach in arthritis and that the biologic effect is enhanced by an emulsome-based adjuvant.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1550-6606
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
185
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3401-7
pubmed:dateRevised
2011-9-19
pubmed:meshHeading
pubmed-meshheading:20720210-Adjuvants, Immunologic, pubmed-meshheading:20720210-Animals, pubmed-meshheading:20720210-Antibodies, Monoclonal, pubmed-meshheading:20720210-Antigens, CD3, pubmed-meshheading:20720210-Arthritis, Experimental, pubmed-meshheading:20720210-Cell Differentiation, pubmed-meshheading:20720210-Cells, Cultured, pubmed-meshheading:20720210-Collagen Type II, pubmed-meshheading:20720210-Emulsions, pubmed-meshheading:20720210-Male, pubmed-meshheading:20720210-Mice, pubmed-meshheading:20720210-Mice, Inbred DBA, pubmed-meshheading:20720210-Mouth Mucosa, pubmed-meshheading:20720210-Nasal Mucosa, pubmed-meshheading:20720210-Peptides, pubmed-meshheading:20720210-Protein Precursors, pubmed-meshheading:20720210-T-Lymphocytes, Regulatory, pubmed-meshheading:20720210-Th2 Cells, pubmed-meshheading:20720210-Transforming Growth Factor beta, pubmed-meshheading:20720210-Up-Regulation
pubmed:year
2010
pubmed:articleTitle
Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant.
pubmed:affiliation
Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural